About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, April 1st, 2013

The QualityStocks
Daily Stock List


Health Enhancement Products, Inc. (HEPI)

Wall Street Resources reported recently on Health Enhancement Products, Inc. (HEPI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Health Enhancement Products, Inc. is a health and wellness company that lists on the OTC Markets' OTCQB. The Company's commitment is to the study, development and commercialization of naturally derived compounds and bioactive molecules created by algal and bacterial hosts. They engage in the research and development of products derived from algae cultures for use as dietary supplements and food ingredients in the U.S. Health Enhancement Products has their corporate headquarters in Bloomfield Hills, Michigan.

Health Enhancement Products markets their products through distributors. The products are extracted from living algae grown in purified water. The Company works to fully extract the beneficial effects of their natural bioactive agents and make them available at a good value in a useful, convenient form.

The Company offers ProAlgaZyme, an infusion of algal metabolites diluted in purified water. These metabolites are created by algae colonies living in special culture tanks housed at Health Enhancement Products' facilities in Scottsdale, Arizona. Concerning Natural Products, the Company has started isolation, development and commercialization of their proprietary algal metabolites tailored to specific applications and targeting specific conditions.

Concerning Derivatives, the immediate and most recent developments at Health Enhancement Products are synthetic or engineered derivatives based on biological molecules and complexes. Pertaining to research and development, the Company's dedication is to rigorous scientific testing, peer review and regulatory compliance.

Health Enhancement Products has started study and development, which targets skeleto-muscular inflammation due to exertion and strenuous exercise; allergies and allergic reactions; cardiovascular disease risk; autoimmune disorders, as well as metabolic functions.

The Company has implemented a new business model whereby they expect to garner future income from licensing and selling natural bioactive ingredients derived from their algae cultures to much larger, better-financed food, dietary supplement and medical food manufacturers. The generation of the anticipated income streams are to be from royalties and advances for licensed natural bioactive ingredients, and bulk sales of such ingredients. They expect that contracted ingredient manufacturers will manufacture these bulk ingredients. Health Enhancement Products will subsequently sell them to food, dietary supplement and medical food processors and/or name-brand marketers.

Health Enhancement Products, Inc. (HEPI), closed Monday at $0.3574, up 17.18%, on 266,247 volume with 49 trades. The average volume for the last 60 days is 135,113 and the stock's 52-week low/high is $0.09/$0.334.

Abtech Holdings, Inc. (ABHD)

Wall Street Resources, FeedBlitz, Greenbackers, and Wyatt Investment Research reported earlier Abtech Holdings, Inc. (ABHD), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Abtech Holdings, Inc. is a full-service environmental technologies and engineering firm whose shares trade on the OTC Markets' OTCQB. AbTech Industries, Inc. is a subsidiary of AbTech Holdings.

Their commitment is to providing creative solutions to communities, industry and governments addressing issues of water pollution and contamination. They offer solutions for Stormwater Management, Oil & Gas Water Treatment, and Industrial Water Treatment. Abtech Holdings has their headquarters in Scottsdale, Arizona.

AbTech integrates their native advanced technologies along with third-party technologies and systems to provide effective and economical solutions to their customers. The basis of the Company's products are on polymer technologies that can remove hydrocarbons, sediment and other foreign elements in storm water runoff, flowing water, and industrial process and wastewater. Their offerings include the antimicrobial technology- Smart Sponge® Plus. This technology is effective in reducing coliform bacteria found in storm water, industrial wastewater, and municipal wastewater. Smart Sponge® Plus is registered with the Environmental Protection Agency (Registration #86256-1).

AEWS Engineering is a subsidiary of Abtech Holdings. AEWS is an independent civil and environmental engineering firm partnered with top research and engineering universities.

Recently, Abtech Holdings announced that they received notification of an award to upgrade an outflow pipe discharging into a beach located on the shores of the Great Lakes using the Company's Smart Sponge® Plus technology. AbTech's Smart Sponge® Plus will be used to filter the storm water drainage coming from lands that border the beach area. This will reduce bacteria concentrations in the discharged water.

Last week, Abtech Holdings reported financial results for their year ended December 31, 2012. For full year 2012, they reported revenues of $717,000. This represents an increase from $537,000 for the prior year. They reported a net loss of $(10.4) million or $(0.19) per basic share for the full year 2012. This is in comparison to a net loss of $(5.4) million or $(0.11) per basic share for the full year 2011.

In 2012, Abtech received many notable awards recognizing Smart Sponge® as an effective filtration technology. These awards include the Artemis Top 50 Water Tech Listing™ and the World Shale Oil & Gas industry a "Technological Innovator" award.

Abtech Holdings, Inc. (ABHD), closed Monday's session at $0.74, up 10.45%, on 263,162 volume with 83 trades. The average volume for the last 60 days is 172,398 and the stock's 52-week low/high is $0.502/$1.15.

Astur Gold Corp. (AST.V)

FutureMoneyTrends.com reported earlier on Astur Gold Corp. (AST.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Astur Gold Corp. engages in the acquisition and exploration of mineral properties in Western Europe, mainly exploring for gold. The Company is developing their 100 percent owned Salave Gold Project in Asturias, northern Spain. This is one of the largest undeveloped gold deposits in Western Europe. The Company formerly went by the name Dagilev Capital Corp. They changed their name to Astur Gold Corp. in June 2010.  Astur Gold's shares trade on the TSX Venture Exchange. Incorporated in 2007, the Company is based in Vancouver, British Columbia.

In November 2012, Astur Gold received approval for an underground mine from the Commission for Environmental Affairs of the Principality of Asturias. The Company is completing additional requirements for the processing plant and tailings licenses. They are working to build a partnership with the people of Asturias to generate sustainable economic benefits for the region. This is while balancing the needs of environmental protection and social community development.

The Salave Gold Project in Asturias consists of 3198 hectares. Salave has an NI 43-101 compliant mineral resource estimate (by Scott Wilson RPA) containing 1,683,000 oz of gold in the Measured & Indicated category (2,155,000 tonnes grading 3.88 g/t Au Measured and 15,790,000 tonnes grading 2.79 g/t Au Indicated) with an additional 338,000 oz of gold in the Inferred category (3,770,000 tonnes grading 2.8 g/t Au).

Furthermore, Astur Gold has their La Codosera Gold Property. It consists of five mineral Investigation Permits covering an area of 1,851 hectares. La Codosera is 40 km from the provincial capital of Badajoz of the Extremadura region of eastern Spain.

In March, Astur Gold announced the closing of the non-brokered private placement announced on February 25, 2013. They issued 2,275,072 units at $0.70 for gross proceeds of $1,592,550.40. This is an increase from the original $1,000,000 announced on February 25, 2013. They will use the proceeds of the private placement to finance exploration and development work on their Salave gold project, and for general working capital purposes.

In addition, last month, Astur Gold announced that Dr. Patrick Moore has joined the Company's Board as an independent Director. Dr. Moore is one of the most distinguished leaders in the field of environmental sustainability. His career spans more than four decades. He co-founded Greenpeace.

Astur Gold Corp. (AST.V), closed Monday's trading session at $0.60, down 6.25%, on 8,100 volume. The stock's 52-week low/high is $0.52/$1.30.

Dial Global, Inc. (DIAL)

StreetInsider and SmarTrend Newsletters reported previously on Dial Global, Inc. (DIAL), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Dial Global, Inc. conducts business as an independent, full-service network radio company in the United States. The Company has their radio networks, heard by over 225 million listeners weekly. Dial Global produces more than 200 news, sports, talk, music and entertainment programs, services and digital applications, jingles and imaging. The Company is the nation's leading independent provider of audio content to radio stations and audio activation solutions to marketing partners. Dial Global lists on the OTC Market's OTC Pink Current Information.

Dial Global is the nation's leading provider and distributor of audio content to more than 8,500 radio stations in the U.S. They distribute, produce, and/or syndicate programming and services to these radio stations. In addition, they offer audio content from live events, turnkey music formats, and prep services. Moreover, they provide interactive voice response (IVR) phone systems that help radio stations answer phones; and they facilitate call-ins, contesting, text messaging, and polling.

Dial Global also operates as a sales representative for independent third party providers of audio content. Furthermore, they provide sales networks to advertisers through a variety of programming and services. They additionally offer their services via 17 owned and operated websites.

For content producers, the Company offers a full-service partnership. Industry veterans manage their traffic, research and sales teams.
For advertisers, Dial Global offers sales networks with first-rate market coverage and strong targeting via their broad selection of programming and station services. These include personality programming, digital formats, news and information services, prep packages, music libraries and interactive technologies. They package their on-air, digital and live event assets into integrated marketing programs for advertisers.

Last month, Dial Global announced that Mr. Paul Caine would become their CEO and a member of the Company's Board of Directors, effective April 5, 2013. Mr. Caine, over the past 23 years at Time, Inc., has led the development of digital formats for some of the world's most storied media brands. He joins Dial Global to create a new opportunity for the Company to expand the marketing and monetization of audio, starting with their lineup of premier sports, entertainment and news content.

Dial Global, Inc. (DIAL), closed Monday's session at $0.33, up 6.45%, on 7,000 volume with 2 trades. The average volume for the last 60 days is 23,868 and the stock's 52-week low/high is $0.16/$0.55.

MRI Interventions, Inc. (MRIC)

Wall Street Resources reported recently on MRI Interventions, Inc. (MRIC), Real Pennies, FeedBlitz did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, MRI Interventions, Inc. is a medical device company based in Memphis, Tennessee. They develop and commercialize unique platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. Using a hospital's existing MRI suite, the design of their FDA-cleared ClearPoint® system is to enable a range of minimally invasive procedures in the brain.

MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint system. The Company is also working with Boston Scientific to incorporate their MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications.

The ClearPoint system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite.  ClearPoint procedures can be used with 1.5T and 3T scanners. ClearPoint is an integrated system of hardware components, disposable components and intuitive, menu-driven software.
MRI Interventions, in collaboration with Siemens Healthcare, is developing the ClearTrace® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias; this includes atrial fibrillation. The Company's interventional platforms work to improve patient care while reducing procedure costs and times.

Last week, MRI Interventions' neurosurgical navigation platform, the ClearPoint® Neuro Intervention System, was featured on the Fox News Health website in a story published on March 25, 2013.  Fox News reporter Laurie Tarkan, in her story titled "MRI-guided brain surgery easier on Parkinson's patients," recounted her interview with Dr. Hooman Azmi, director of the division of movement disorders at Hackensack University Medical Center in New Jersey, regarding his experience using the ClearPoint system in deep brain stimulation (DBS) surgeries.

The story conveys some of the drawbacks of the traditional DBS surgery. It notes that surgeons have started using the ClearPoint system to address those negative aspects of the procedure. Deep brain stimulation (DBS) is a surgical option for treating the symptoms of Parkinson's disease.

MRI Interventions, Inc. (MRIC), closed Monday's trading session at $1.20, down 0.83%, on 39,592 volume with 26 trades. The average volume for the last 60 days is 89,214 and the stock's 52-week low/high is $0.74/$5.00.

Applied DNA Sciences, Inc. (APDN)

Greenbackers, Real Pennies, Stock Analyzer, OTCPicks, and ThePUMPTracker reported earlier on Applied DNA Sciences, Inc. (APDN), and we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Applied DNA Sciences, Inc. is a provider of DNA-based anti-counterfeiting technology and product authentication solutions. SigNature® DNA and smartDNA are their principal anti-counterfeiting and product authentication solutions. The Company has patented technologies and commercial solutions that provide the most advanced forensic features available. Applied DNA Sciences has their corporate headquarters in Stony Brook, New York. The Company lists on the OTC Bulletin Board.

Applied DNA Sciences provides botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA essentially cannot be copied. They provide a forensic chain of evidence; they can be used to prosecute perpetrators.

SigNature DNA is a unique DNA marker designed to mark an original item. SigNature DNA markers can be used to strengthen brand protection efforts; mark, track and convict criminals; and help to secure supply chains. The Company's solutions include BioMaterial GenoTyping™ - genomic DNA present in a natural material that is used to authenticate a product. In addition, their FiberTyping™ textile genotyping is a commercial test that can differentiate between Pima and Upland cotton from fiber to finished fabric and apparel. It adds accountability to all stages of the textile manufacturing process.

In February 2013, Applied DNA Sciences announced the activation of an agreement with the Defense Logistics Agency for authentication services and training. The contract (signed in November 2012) was activated with the delivery of the first services by the Company to Defense Logistics Agency. The yearlong contract, with a maximum value of $150,000, represents Applied DNA Sciences' first direct business with a federal U.S. government agency.

Recently, Applied DNA Sciences announced that Mr. Chris Taylor joined the Company as Director, Europe. Mr. Taylor is a recognized leader in forensic marking products. He will help lead Applied DNA Sciences in comprehensively expanding their offerings in the UK, the European continent, and in Scandinavia. Mr. Taylor formerly was Managing Director of RedWeb Technologies.

Applied DNA Sciences, Inc. (APDN), closed Monday's trading session at $0.235, up 2.62%, on 14,520,603 volume with 1,264 trades. The average volume for the last 60 days is 1,899,233 and the stock's 52-week low/high is $0.021/$0.305.

Global Security Agency, Inc. (GSAG)

PickPennyStocks, Growing Stocks Reports, Research Driven Alerts, Michael Stone, Stockdigest Report, Research Driven Investor, PennyStocks24, PennyTrader, SmallCapInvestorDaily, PennyStockScholar, and OTCtipReporter reported last week on Global Security Agency, Inc. (GSAG), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Based in Conroe, Texas, Global Security Agency, Inc. is an enterprise that provides global executive protection. They provide security and risk management services to wealthy individuals, corporations, and other entities around the world. These services include risk assessments, training, crisis management, protection, support and intelligence. Global Security Agency's shares trade on the OTCQB.

Global Security Agency is a licensed private protection agency consisting of career law-enforcement officers, military and specialized personnel. All of their employees are CCT (Close Combat Trained) certified, with firearms and other weaponry. The Company operates their business through a network of consultants who are experts in the field of crisis management. They have substantial government, military, foreign services and private industry experience.

The Company's commitment is to on-site protection that ensures immediate and instant response to any threat against a client and their family or property. Global Security Agency has specialized security capacity, home security, event protection and coverage, workplace violence, employee termination, labor disputes, board meeting, executive protection and kidnapping resolutions. 

The Company has historically been the leading provider in logistics, support training, security intelligence work and risk analysis for corporations, and families around the world. They are now offering the same expertise that has been available to their corporate clients to family law practitioners, and their clients in the State Of Texas. Pertaining to Family Law Services, the Company offers all civil process services (subpoenas, citations, and more). Moreover, they provide private and forensic investigations; personal protection; Training: In Home CHL Training; Risk & Threat Assessments, and 24/7 Private Security.

In February, the Company announced that they authorized an agreement with their new partner, Risk Management, to begin the development of the first Personal Protection Academy in mainland China. The facilities will be maintained and instructed by American Trainers.

Recently, Global Security Agency announced that they were selected as one of the training companies identified to help train security and police forces in Mexico.  The Company continues their support of the Mexican security forces and the newly elected Mexican leadership led by President Enrique Pena Nieto.

Global Security Agency, Inc. (GSAG), closed Monday's trading at $0.011, down 41.18%, on 7,061,883 volume with 199 trades. The average volume for the last 60 days is 1,255,447 and the stock's 52-week low/high is $0.002/$0.08.

Maxwell Resources, Inc. (MAXE)

PennyStocks24, Penny Stocks VIP, Penny Stock Circle, 1-2-3 Stock Alerts, StockMarketQuote.us, PennyStockClub, The Stock Scout, Penny Stock Pros, OTC Journal, Otcstockexchange, Whisper from Wall Street, TooNiceStocks, Stock Brain, Stockhunter.us, VIP STOCK ALERTS, HEROSTOCKS, and Liquid Pennies reported on Maxwell Resources, Inc. (MAXE), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Las Vegas, Nevada, Maxwell Resources, Inc. engages in natural resource mining and exploration. The Company has acquired certain gold, silver, iron ore, copper and coal interests in New Mexico. They own mineral rights (fee simple) for over 170,000 acres in the Raton Basin in northern New Mexico's Colfax County. Maxwell Resources' goal is the exploration of the Raton Basin for potential energy and valuable metals reserves.  The Company formerly went by the name Mericol, Inc. They changed their name to Maxwell Resources, Inc. in September of 2012. Maxwell Resources lists on the OTC Bulletin Board.

Effective July 27, 2012, pursuant to a Contract for sale with Sun River Energy, Inc., Maxwell Resources acquired certain gold, silver, iron ore, copper and coal interests in Colfax County. As additional consideration for the purchase of the mineral assets, the Company was also granted a three-year option to acquire a five percent working interest (WI) in any oil and/or gas (including coalbed methane) wells drilled on any properties owned by Sun River in New Mexico.

The Raton Basin in northern New Mexico has potential as a premier source of coking coal, gold, silver and other rare minerals. Maxwell Resources' intention is to prove up on the coal, gold/silver and other rare minerals within the basin, pinpointing the sites that will result in the largest return on investment. The Raton Basin is located in what once was the largest land grant in New Mexico history – namely, the Maxwell Land Grant. The Raton Basin is between Dawson and Elizabethtown, New Mexico, approximately three hours north of Albuquerque and one hour north of Taos.

The United States Geological Survey (USGS) has studied the region; the basin contains potentially $3.4 billion in metallurgical (coking) coal, according to 1991 USGS estimates. A 2005 study indicates there could be even more high-grade coal than the USGS previously estimated. (Pillmore 1991, USGS Bulletin, No. 1972) (Hoffman Report, 2005).

On February 15, 2013, Maxwell Resources reported that Golder Associates presented a draft of their preliminary study of Maxwell's mineral rights holdings in the Raton Basin; they identified two areas that indicate the viability for proving up gold.

Mr. Phillip Dias, Maxwell Resources' President and Chief Executive Officer, said, "The report has pinpointed two areas with gold potential that are viable for Phase 2 of our study which will include, sampling, trending and modest drilling programs."

Maxwell Resources, Inc. (MAXE), closed Monday at $0.078, down 7.14%, on 126,982 volume with 16 trades. The average volume for the last 60 days is 239,705 and the stock's 52-week low/high is $0.05/$1.15.


The QualityStocks
Company Corner


Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.109, up 22.47%, on 1,512,861 volume with 98 trades. The stock’s average daily volume over the past 60 days is 4,606,314, and its 52-week low/high is $0.0275/$0.155.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop

Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards

Advaxisí ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma

Rainbow Coral Corp. (RBCC)

The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.118, up 6.98%, on 277,775 volume with 44 trades. The stock’s average daily volume over the past 60 days is 154,460, and its 52-week low/high is $0.11/$2.67.

Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.

Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.

The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.

The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer

Rainbow Coral Corp. Company Blog

Rainbow Coral Corp. News:

RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing

RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine

RBCC Tech Innovations Drive Big Growth in $60 Billion Drug Delivery Market

VentriPoint Diagnostics Ltd. (VPTDF)

The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.10, up 6.38%, on 170,000 volume with 11 trades. The stock’s average daily volume over the past 60 days is 58,072, and its 52-week low/high is $0.073/$0.1721.

VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.

VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.

The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer

VentriPoint Diagnostics Ltd. Company Blog

VentriPoint Diagnostics Ltd. News:

VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease

VentriPoint Announces $2 Million Unit Private Placement

VentriPoint Receives US-FDA Acceptance of 510 (K) Submission for Pulmonary Arterial Hypertension

Soul and Vibe Interactive, Inc. (SOUL)

The QualityStocks Daily Newsletter would like to spotlight Soul and Vibe Interactive, Inc. (SOUL). Today, Soul and Vibe Interactive, Inc. closed trading at $0.36, up 2.86%, on 167,581 volume with 63 trades. The stock’s average daily volume over the past 60 days is 218,213, and its 52-week low/high is $0.26/$1.45.

Soul and Vibe Interactive, Inc. (SOUL) is a publisher of games and game-related content for consoles, mobile devices, and personal computers. The company specializes in creating original intellectual properties and has extensive experience licensing world-renowned brands from influential companies. Notably, Soul and Vibe is the only company with the right to license General Mills brands for video game applications. 

Leveraging partnerships with software developers around the world, Soul and Vibe transforms unique concepts into engaging and affordable entertainment experiences. The game publisher has established game development and publishing agreements for the Xbox 360® video game and entertainment system, Windows 8, Windows Live, and Windows Phone from Microsoft, and the PlayStation® 3 computer entertainment system and PlayStation® Vita (PS Vita) from Sony.

Soul and Vibe stands out from the crowd by breaking through marketplace clutter and noise via direct-to-consumer tactics that reverberate from the core player to the mainstream gaming audience. Making games as fun to talk about as they are to play is a key focus of the company. The more personable and memorable the play experience, the more likely consumers and press will talk about the game and its publisher.

The burgeoning game industry spans across diverse demographics and offers wide-ranging opportunities for profit and growth. Consumer spending on console, mobile, and personal computer game software exceeded $56 billion in 2010 and is projected to reach $82 billion by 2015. This revenue represents more than 2x the size of the music industry and nearly 3/5th the size of the entire film industry. Disclaimer

Soul and Vibe Interactive, Inc. Company Blog

Soul and Vibe Interactive, Inc. News:

Soul and Vibe to Build Micro-Transactions Into Its Console, Mobile, and PC Games

Soul and Vibe to Pursue Business Development Deals at Game Connection Conference in San Francisco

Soul and Vibe to Monetize Avatars to Create Marketing Impressions and Additional Revenues

The Guitammer Company, Inc. (GTMM) Launches Music into a New Dimension

When it comes to music, nobody takes things more seriously than professional musicians, the people whose livelihood depends upon getting it right. They’re passion for the music experience is what drives them, and, of course, it’s also what drives their fans. So when you have a creative new product designed to add a new dimension to that experience, and it has already been picked up by 100 of the world’s top bands and performers, names like the Rolling Stones and Shania Twain and Usher, you know you’ve hit a chord.

Such is the case with the ButtKicker Concert, Guitammer’s patented 2-ohm audio transducer that turns low-frequency sounds into tactile chair vibrations, raising the music experience bar for both performers and listeners. The technology behind ButtKicker Concert has spread rapidly, and is now being used by companies like IMAX, Disney, and AMC to enhance the entertainment experience of customers all over the world. For musicians, it means that the low-end response for their stage, studio, or rehearsal room monitoring can now be powerful and incredibly tight, with every beat actually felt as well as heard. It’s musically accurate, with powerful frequency response of approximately 5Hz to 200Hz, yet is essentially indestructible, requiring no maintenance. Drummers, bass players, keyboardists, and even DJs, say that the system allows them to perform better than ever before.

Realizing they were on to something hot, the company has also hit the home listener market. The Wireless ButtKicker Kit lets the listener feel the music just like they were at a live performance, without having to increase the volume to problematic or even dangerous levels. It’s experiencing recorded music as never before, making even a basic speaker system seem like state-of-the-art audio.

Click http://dtg.fm/sT67 to hear professional drummer Carlton Smith talk about his experience with ButtKicker products.

For more information, visit www.Guitammer.com

Cardium Therapeutics, Inc. (CXM) Addresses the High Cost of Heart Surgery

The number and degree of medical advances over the past 50 years is astonishing, offering hope for the afflicted never before possible or even imaginable. But it’s hope that comes with a very steep price. Regardless of who pays the bill, or how efficiently everything is administered, the cost of applying the latest technologies is going to be high, whether in the form of drugs, diagnostic instrumentation, or complex surgeries. As existing technologies mature, costs can decrease, but the use of mature technologies is inevitably replaced by a demand for even newer drugs, instrumentation, and procedures. When a loved one’s life is at stake, everyone wants the best.

In the case of heart disease, the world’s #1 killer, the costs can be staggering. Angioplasty and stent procedures to improve blood flow to the heart can cost tens of thousands of dollars, and coronary bypass surgery can cost hundreds of thousands of dollars. Multiply such costs by the number of patients who receive coronary revascularizations each year (over a million in the U.S. alone), together with the costs associated with all of the complications that can result, and the impact on healthcare costs becomes clear.

Such numbers drive home the importance of Generx, the lead clinical development product candidate of Cardium Therapeutics. Unlike traditional heart treatment drugs that only treat the pain of heart blood flow problems, requiring expensive procedures like the above to deal with actual blood flow, Generx is able to stimulate the growth of blood vessels in the heart. As a cost-effective and easy-to-apply alternative to invasive procedures, the target market for the drug is deep and worldwide. In countries where the access to technology and associated funding is limited, Generx could represent a desperately needed option. The drug has already completed four randomized clinical studies in the U.S. and Europe.

For additional information, visit www.CardiumTHX.com

International Stem Cell Corp. (ISCO) Makes Major Scientific Strides in 2012

The recent conference call by International Stem Cell Corp., covering sales and other financial data for the 4th quarter and full year for 2012, provided important insights into the prior year’s scientific accomplishments.

In particular, the company made significant progress with their Parkinson’s program, progress which will now be accelerated with the addition of Dr. Evan Snyder, a renowned neurobiologist and head of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee, as a non-compensated member of the company’s Board of Advisors. Dr. Snyder’s help in navigating the complex FDA approval process should help greatly in moving the program into clinical trials over the next 1-2 years. As safety data in humans is accumulated, many other areas should open up for the company, with opportunities in the areas of stroke or traumatic brain injury, a move which could transform the company.

ISCO also successfully completed the first phase in their stem cell banking program, setting up clinics and associated processes, recruiting a pool of donors, as well as generating new clinical grade parthenogenetic stem cell lines for use in future clinical trials. In addition, the company made important advances in their liver program, showing how their cells can be used in the treatment of congenital liver diseases. Patent protection was also received that protects the way liver and pancreas cell precursors are made.

Another important development was a new procedure for producing iPS cells (induced pluripotent stem cells), which should be significantly safer than current approaches that rely on viruses. The growing popularity of iPS cells in regenerative medicine has highlighted the need to overcome two major issues with the cells: (1) The safety of iPS cells is open to question due to the use of viruses, and this is of primary concern to the FDA, and (2) Most intellectual property involving iPS cells is controlled by a handful of organizations, making it difficult and expensive to commercialize a therapeutic product based on this technology. ISCO’s newly developed iPS technology solves both of these problems, since it does not rely on viruses, nor on the intellectual property of others.

For additional information, visit www.InternationalStemCell.com

GlobalWise Investments, Inc. (GWIV) Merges Two Powerhouse Technologies

The story of Intellinetics, subsidiary of GlobalWise Investments, is one of technological convergence, and reflects the growth of information processing and communication over the past 20 years. On one hand, there is the development of ECM (Enterprise Content Management), the digital capture and storage of an organization’s documents for effective access, exemplified by Intellinetics and its lead product Intellivue. On the other hand, you have the burgeoning world of data communications, with the Internet and increasingly capable mobile devices.

Intellinetics began developing data storage solutions in the mid 1990s, about the time people began to realize that computerization was increasing rather than reducing the number of documents being used. The flood of paperwork was becoming unmanageable, and available software was simply not adequate for effective document storage and access. Focusing on flexibility and ease of integration, Intellinetics developed the Intellivue ECM solution, eventually making it a leading choice in mission-critical operating environments for both industry-specific and business function-specific solutions. At first a client server based solution, the company began migrating to a cloud based platform, allowing Intellinetics to bring ECM, once available only to larger organizations, to the mass market, minimizing up-front costs, and maximizing ease of use.

While Intellinetics was busy laying the technological and business model foundation for mass-market ECM, data communication was being transformed through use of the Internet and mobile device technology. Organizations were learning how to communicate data, both internally and externally, to wherever it was needed. Eventually processing power itself became something that could be controlled remotely, especially beneficial with the growth of mobile devices.

Today, these two forces have been brought together. Using their advanced cloud-based ECM offering, together with a partner-based business model, Intellivue provides organizations of all sizes with a powerful ECM solution that is easily integrated into existing enterprise systems. The system is easy to use, minimizing work to capture documents, and making documents available for security-controlled computer or mobile device access from anyplace in the world on a 24/7 basis.

For additional information on GlobalWise and its subsidiary, visit www.GlobalWiseInvestments.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Winning Penny Stock Picks


Real Pennies


OTC Stock Pick

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251